GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (NAS:ORTX) » Definitions » Operating Margin %

Orchard Therapeutics (Orchard Therapeutics) Operating Margin % : -342.83% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Orchard Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Orchard Therapeutics's Operating Income for the three months ended in Sep. 2023 was $-21.61 Mil. Orchard Therapeutics's Revenue for the three months ended in Sep. 2023 was $6.30 Mil. Therefore, Orchard Therapeutics's Operating Margin % for the quarter that ended in Sep. 2023 was -342.83%.

The historical rank and industry rank for Orchard Therapeutics's Operating Margin % or its related term are showing as below:

ORTX' s Operating Margin % Range Over the Past 10 Years
Min: -11321.34   Med: -6879.15   Max: -467.13
Current: -467.13


ORTX's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -177.195 vs ORTX: -467.13

Orchard Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Orchard Therapeutics's Operating Income for the three months ended in Sep. 2023 was $-21.61 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-102.02 Mil.


Orchard Therapeutics Operating Margin % Historical Data

The historical data trend for Orchard Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchard Therapeutics Operating Margin % Chart

Orchard Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial -11,321.34 -6,879.15 -6,049.25 -8,355.16 -559.50

Orchard Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -442.69 -452.22 -2,122.72 -308.48 -342.83

Competitive Comparison of Orchard Therapeutics's Operating Margin %

For the Biotechnology subindustry, Orchard Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchard Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchard Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Orchard Therapeutics's Operating Margin % falls into.



Orchard Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Orchard Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-126.755 / 22.655
=-559.50 %

Orchard Therapeutics's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-21.605 / 6.302
=-342.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orchard Therapeutics  (NAS:ORTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Orchard Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Orchard Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchard Therapeutics (Orchard Therapeutics) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
Executives
Bobby Gaspar director, officer: See Remarks ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Jon Ellis director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Marc Dunoyer director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
John T Curnutte director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Mark Rothera director, officer: See Remarks C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James A Geraghty director C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421

Orchard Therapeutics (Orchard Therapeutics) Headlines

From GuruFocus

Orchard Therapeutics to Present at Stifel's Genetic Medicines Day

By sperokesalga sperokesalga 05-24-2023